Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 11Terminated 6Withdrawn 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Breast 1

Conditions

Solid Tumor 1Liposarcoma 1Breast Neoplasms 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × tanespimycin × Clear all
NCT00820768 2018-04-11

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Celgene

Phase 1 Withdrawn
Other solid neoplasm

Solid Tumor

NCT00969917 2015-04-14

Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Infinity Pharmaceuticals, Inc.

Phase 2 Withdrawn
Sarcoma

Liposarcoma

NCT00627627 2010-02-03

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

MedImmune LLC

Phase 1/2 Withdrawn
56 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡